231 related articles for article (PubMed ID: 32670888)
1. ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy.
Kong J; Yao C; Ding X; Dong S; Wu S; Sun W; Zheng L
Front Oncol; 2020; 10():1080. PubMed ID: 32670888
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.
Song R; Song H; Liang Y; Yin D; Zhang H; Zheng T; Wang J; Lu Z; Song X; Pei T; Qin Y; Li Y; Xie C; Sun B; Shi H; Li S; Meng X; Yang G; Pan S; Zhu J; Qi S; Jiang H; Zhang Z; Liu L
Hepatology; 2014 Nov; 60(5):1659-73. PubMed ID: 25042864
[TBL] [Abstract][Full Text] [Related]
4. LncRNA FUNDC2P4 down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin expression in residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Zeng J; Cai X; Hao X; Huang F; He Z; Sun H; Lu Y; Lei J; Zeng W; Liu Y; Luo R
Int J Hyperthermia; 2018 Sep; 34(6):802-811. PubMed ID: 29295626
[TBL] [Abstract][Full Text] [Related]
5. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Dong S; Kong J; Kong F; Kong J; Gao J; Ke S; Wang S; Ding X; Sun W; Zheng L
J Transl Med; 2013 Oct; 11():273. PubMed ID: 24168056
[TBL] [Abstract][Full Text] [Related]
6. After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma.
Kong J; Kong L; Kong J; Ke S; Gao J; Ding X; Zheng L; Sun H; Sun W
J Transl Med; 2012 Nov; 10():230. PubMed ID: 23171368
[TBL] [Abstract][Full Text] [Related]
7. Circular BANP knockdown inhibits the malignant progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Li G; Kong J; Dong S; Niu H; Wu S; Sun W
Chin Med J (Engl); 2022 Aug; ():. PubMed ID: 35941728
[TBL] [Abstract][Full Text] [Related]
8. Circular BANP knockdown inhibits the malignant progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation.
Li G; Kong J; Dong S; Niu H; Wu S; Sun W
Chin Med J (Engl); 2022 Jan; 135(13):1578-87. PubMed ID: 34985013
[TBL] [Abstract][Full Text] [Related]
9. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins.
Zhang N; Li H; Qin C; Ma D; Zhao Y; Zhu W; Wang L
J Cancer Res Clin Oncol; 2019 Apr; 145(4):895-907. PubMed ID: 30820716
[TBL] [Abstract][Full Text] [Related]
10.
Li Z; Jiang M; Zhang T; Liu S
Cancer Biother Radiopharm; 2021 Dec; 36(10):879-887. PubMed ID: 32799553
[No Abstract] [Full Text] [Related]
11. Platelet lysates in Hepatocellular Carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry.
Jia G; Kong J; Yao C; Wu S; Sun W
Int J Med Sci; 2020; 17(14):2104-2112. PubMed ID: 32922171
[No Abstract] [Full Text] [Related]
12. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells.
Xu GL; Ni CF; Liang HS; Xu YH; Wang WS; Shen J; Li MM; Zhu XL
Gastroenterol Rep (Oxf); 2020 Oct; 8(5):390-398. PubMed ID: 33163195
[TBL] [Abstract][Full Text] [Related]
14. ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma.
Ding X; Kong J; Xu W; Dong S; Du Y; Yao C; Gao J; Ke S; Wang S; Sun W
Oncol Lett; 2018 Oct; 16(4):5230-5236. PubMed ID: 30250592
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
16. Interferon-α Combined With Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model.
Zhang N; Wang LR; Li DD; Ma DN; Wang CH; He XG; Gao DM; Wang L; Tang ZY
Integr Cancer Ther; 2018 Dec; 17(4):1260-1269. PubMed ID: 30234394
[TBL] [Abstract][Full Text] [Related]
17. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Zhang Q; Kong J; Dong S; Xu W; Sun W
Cancer Cell Int; 2017; 17():48. PubMed ID: 28450808
[TBL] [Abstract][Full Text] [Related]
18. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
19. ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation.
Kong J; Yao C; Dong S; Wu S; Xu Y; Li K; Ji L; Shen Q; Zhang Q; Zhan R; Cui H; Zhou C; Niu H; Li G; Sun W; Zheng L
Adv Sci (Weinh); 2021 Feb; 8(4):2002228. PubMed ID: 33643788
[TBL] [Abstract][Full Text] [Related]
20. c-Met/MAPK pathway promotes the malignant progression of residual hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Jia G; Li F; Tong R; Liu Y; Zuo M; Ma L; Ji X
Med Oncol; 2020 Nov; 37(12):117. PubMed ID: 33215351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
